Partnerships for clinical innovation

Establishing partnerships

• 
  As content experts in specific scientific areas, they can collaborate on the development of relevant research questions.
  
• 
  Based on their familiarity with available data at their site, HMORN investigators can inform study designs that are efficient and feasible, thus optimizing many aspects of the study process ranging from data capture to participant recruitment.
  
• 
  Similarly, many HMORN researchers have gained familiarity with data structures and analytic processes across other HMORN sites, facilitating cross-site collaboration.
  
• 
  The scientific teams also have well-developed networks of collaborators who can contribute to methodological and operational aspects of working in the healthcare environment itself; as studies are completed, the HMORN-based researcher is well-positioned to ensure that relevant findings receive consideration in clinical practice.
  

HMORN researchers have extensive experience conducting collaborative projects both within the network and with external collaborators. Typical collaborators include other HMORN members, regional universities, Clinical and Translational Science Award networks, regional and disease-specific research networks and public health departments.

Obtaining and managing funding

HMORN sites primarily conduct federally-funded investigator-initiated research, and function similarly to academic departments, inasmuch as the HMORN scientists write and compete for grants, and engage with federal sponsors to complete funded investigations. Each site has its own unit that handles grants and contracts as well as human subjects and regulatory compliance to efficiently meet federal reporting standards.

Figure 3a: Kaiser Permanente Division of Research Collaboration Web Portal

_____________________________________________________________________________________________

Figure 3b: Geisinger Center for Clinical Studies Study Lifecycle Management Flow

For every potential clinical study, the Geisinger Center for Clinical Studies (CCS) conducts a Feasibility Analysis, which frequently includes an EMR data pull to determine the volume of potentially eligible patients. From the Feasibility Analysis, Geisinger can propose realistic enrollment expectations for the study sponsor. CCS has also developed an Enrolling and Retention Strategy Document that evaluates the factors contributing to successful participation, enrollment and retention, and contingency plans for each step. CCS staff follow a standard process for ongoing studies to provide scheduled updates on enrollment and retention. Triggers for implementing contingency plans as outlined in the Enrollment and Retention Strategy are identified as a result of these updates. This process is depicted below.

Abbreviations: PAF = protocol assessment form; EARSD = Enrollment and Retention Strategy Document;

CRC = clinical research coordinator; EU = Enrollment update; RU = Retention update

Download 2.16 Mb.

Share with your friends: